MX2009010211A - Proceso de intermediarios para la sintesis de compuestos 8-[{1-(3,5-bis-(trifluorometil)fenil)-etoxi}-metil]-8-fenil-1,7-d iaza-espiro[4.5]decan-2-ona. - Google Patents
Proceso de intermediarios para la sintesis de compuestos 8-[{1-(3,5-bis-(trifluorometil)fenil)-etoxi}-metil]-8-fenil-1,7-d iaza-espiro[4.5]decan-2-ona.Info
- Publication number
- MX2009010211A MX2009010211A MX2009010211A MX2009010211A MX2009010211A MX 2009010211 A MX2009010211 A MX 2009010211A MX 2009010211 A MX2009010211 A MX 2009010211A MX 2009010211 A MX2009010211 A MX 2009010211A MX 2009010211 A MX2009010211 A MX 2009010211A
- Authority
- MX
- Mexico
- Prior art keywords
- decan
- pheny
- diaza
- trifluoromethyl
- ethoxy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/38—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
Abstract
La presente solicitud revela un proceso novedoso para sintetizar compuestos de 8-[{1-(3,5-Bis-(trifluorometil)fenil)-etoxi}-metil}- 8-fenil-1,7-diaza-espiro[4,5]decan-2-ona, los cuales se pueden utilizar, por ejemplo, como compuestos inhibidores de NK-1 en preparaciones farmacéuticas.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US91966607P | 2007-03-22 | 2007-03-22 | |
PCT/US2008/003640 WO2008118328A2 (en) | 2007-03-22 | 2008-03-20 | Process and intermediates for the synthesis of 8-[{1-(3,5-bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2009010211A true MX2009010211A (es) | 2009-10-19 |
Family
ID=39789180
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2009010211A MX2009010211A (es) | 2007-03-22 | 2008-03-20 | Proceso de intermediarios para la sintesis de compuestos 8-[{1-(3,5-bis-(trifluorometil)fenil)-etoxi}-metil]-8-fenil-1,7-d iaza-espiro[4.5]decan-2-ona. |
Country Status (11)
Country | Link |
---|---|
US (3) | US8552191B2 (es) |
EP (2) | EP2137151B1 (es) |
JP (2) | JP5451404B2 (es) |
CN (2) | CN101679257B (es) |
AR (1) | AR066191A1 (es) |
CA (1) | CA2682221C (es) |
ES (1) | ES2579771T3 (es) |
HK (1) | HK1136297A1 (es) |
MX (1) | MX2009010211A (es) |
SG (1) | SG182226A1 (es) |
WO (1) | WO2008118328A2 (es) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG10201500028RA (en) | 2006-04-05 | 2015-02-27 | Opko Health Inc | Pharmaceutical formulations: salts of 8-[{1-(3,5-bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and treatment methods using the same |
AR060353A1 (es) | 2006-04-05 | 2008-06-11 | Schering Corp | Sales de hidrocloruro de 8 - [( 1- (3,5 -bis- (trifluorometil) fenil) -etoxi) -metil] -8-fenil-1,7 -diaza- spiro [4.5] decan -2-ona. composiciones farmaceuticas |
AR066191A1 (es) | 2007-03-22 | 2009-08-05 | Schering Corp | Proceso e intermediarios para la sintesis de compuestos 8- [ ( 1- (3,5- bis- ( trifluorometil) fenil) - etoxi ) - metil]- 8 fenil - 1,7- diaza - espiro (4, 5) decan -2 ona |
HUE026148T2 (en) * | 2008-09-05 | 2016-05-30 | Opko Health Inc | 8 - ({1- [3,5-bis (trifluoromethyl) phenyl] ethoxy} methyl) -8-phenyl-1,7-diaza-spiro [4,5] decane-on-compounds intermediates |
ES2609640T3 (es) * | 2009-08-14 | 2017-04-21 | Opko Health, Inc | Formulaciones intravenosas de rolapitant |
GB2504076A (en) | 2012-07-16 | 2014-01-22 | Nicoventures Holdings Ltd | Electronic smoking device |
GB2504075A (en) | 2012-07-16 | 2014-01-22 | Nicoventures Holdings Ltd | Electronic smoking device |
GB201505595D0 (en) | 2015-03-31 | 2015-05-13 | British American Tobacco Co | Cartridge for use with apparatus for heating smokeable material |
CN105017251B (zh) * | 2015-06-30 | 2018-06-29 | 齐鲁制药有限公司 | 一种nk-1受体拮抗剂的制备方法及其中间体 |
JP6384536B2 (ja) * | 2015-10-23 | 2018-09-05 | 信越化学工業株式会社 | フッ化イットリウム溶射材料及びオキシフッ化イットリウム成膜部品の製造方法 |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3094522A (en) * | 1961-07-25 | 1963-06-18 | Merck & Co Inc | Alkanoylthio and pyrazolo androstane derivatives |
US5620989A (en) | 1992-10-28 | 1997-04-15 | Merck Sharp & Dohme Limited | 4-Arylmethyloxymethyl piperidines as tachykinin antagonsits |
EP0673367A1 (en) | 1992-12-14 | 1995-09-27 | MERCK SHARP & DOHME LTD. | 4-aminomethyl/thiomethyl/sulfonylmethyl-4-phenylpiperidines as tachykinin receptor antagonists |
EP0739336B1 (en) | 1994-01-13 | 1998-08-26 | MERCK SHARP & DOHME LTD. | Gem-disubstituted azacyclic tachykinin antagonists |
GB9601680D0 (en) | 1996-01-27 | 1996-03-27 | Pfizer Ltd | Therapeutic agents |
GB9626746D0 (en) | 1996-12-23 | 1997-02-12 | Knoll Ag | Process |
JP2001523245A (ja) | 1997-04-24 | 2001-11-20 | メルク シヤープ エンド ドーム リミテツド | 肥満を治療するためのnk−1受容体拮抗薬およびssriの使用 |
DE19815275B4 (de) | 1998-04-06 | 2009-06-25 | Evonik Degussa Gmbh | Alkylidenkomplexe des Rutheniums mit N-heterozyklischen Carbenliganden und deren Verwendung als hochaktive, selektive Katalysatoren für die Olefin-Metathese |
US6215019B1 (en) | 1998-09-01 | 2001-04-10 | Tilliechem, Inc. | Synthesis of 5-decenyl acetate and other pheromone components |
WO2000038677A1 (en) | 1998-12-23 | 2000-07-06 | Allelix Biopharmaceuticals Inc. | Indole and indolizidine derivatives for the treatment of migraine |
JP4410422B2 (ja) | 1999-05-24 | 2010-02-03 | カリフォルニア インスティチュート オブ テクノロジー | イミダゾリジンに基づく金属カルベンメタセシス触媒 |
US6858414B2 (en) * | 1999-12-01 | 2005-02-22 | BIOGAL Gyógyszergyár Rt. | Multistage process for the preparation of highly pure deferoxamine mesylate salt |
US6436928B1 (en) | 1999-12-17 | 2002-08-20 | Schering Corporation | Selective neurokinin antagonists |
ATE318259T1 (de) | 1999-12-17 | 2006-03-15 | Schering Corp | Selektive neurokinin-antagonisten |
GB0004699D0 (en) | 2000-02-28 | 2000-04-19 | Merck Sharp & Dohme | Chemical synthesis |
AU2001284773B2 (en) | 2000-08-10 | 2004-08-05 | Trustees Of Boston College | Recyclable metathesis catalysts |
TW200300347A (en) | 2001-11-13 | 2003-06-01 | Schering Corp | Nk1 antagonists |
PE20030762A1 (es) * | 2001-12-18 | 2003-09-05 | Schering Corp | Compuestos heterociclicos como antagonistas nk1 |
EP1536797B1 (en) | 2002-07-03 | 2007-04-04 | Schering Corporation | 1-amido-4-phenyl-4-benzyloxymethyl-piperidine derivatives and related comounds as neurokinin-1 (nk-1) antagonsists for the treatment of emesis, depression, anxiety and cough |
PL199412B1 (pl) | 2002-10-15 | 2008-09-30 | Boehringer Ingelheim Int | Nowe kompleksy rutenu jako (pre)katalizatory reakcji metatezy, pochodne 2-alkoksy-5-nitrostyrenu jako związki pośrednie i sposób ich wytwarzania |
CA2522946A1 (en) * | 2003-04-23 | 2004-11-04 | Merck & Co., Inc. | Selective spirocyclic glucocorticoid receptor modulators |
US20050153999A1 (en) * | 2003-12-22 | 2005-07-14 | Schering Corporation | Pharmaceutical compositions |
JP2007532561A (ja) * | 2004-04-07 | 2007-11-15 | シェーリング コーポレイション | 縮合環nk1アンタゴニスト |
HUE027791T2 (en) | 2004-07-01 | 2016-11-28 | Opko Health Inc | Piperidine derivatives as NK1 antagonists |
JP4444745B2 (ja) | 2004-07-08 | 2010-03-31 | キヤノン株式会社 | 偏光分離素子および画像投射装置 |
US7354922B2 (en) * | 2004-12-14 | 2008-04-08 | Schering Corporation | Bridged ring NK1 antagonists |
TW200630380A (en) | 2005-02-18 | 2006-09-01 | Nat Univ Chung Hsing | N-acylamino acid racemase of Deinococcus radiodurans and producing method thereof, and L-amino acid production method therefrom |
EP2886549A1 (en) | 2005-07-04 | 2015-06-24 | Zannan Scitech Co., Ltd. | Ruthenium complex ligand, ruthenium complex and the use of the complex as a catalyst in olefin metathesis reactions |
AR060353A1 (es) * | 2006-04-05 | 2008-06-11 | Schering Corp | Sales de hidrocloruro de 8 - [( 1- (3,5 -bis- (trifluorometil) fenil) -etoxi) -metil] -8-fenil-1,7 -diaza- spiro [4.5] decan -2-ona. composiciones farmaceuticas |
SG10201500028RA (en) | 2006-04-05 | 2015-02-27 | Opko Health Inc | Pharmaceutical formulations: salts of 8-[{1-(3,5-bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and treatment methods using the same |
TW200806666A (en) | 2006-04-05 | 2008-02-01 | Schering Corp | Salts of 8-[(1-(3,5-bis-(trifluoromethyl)phenyl)-ethoxy)-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and preparation process therefor |
AR066191A1 (es) | 2007-03-22 | 2009-08-05 | Schering Corp | Proceso e intermediarios para la sintesis de compuestos 8- [ ( 1- (3,5- bis- ( trifluorometil) fenil) - etoxi ) - metil]- 8 fenil - 1,7- diaza - espiro (4, 5) decan -2 ona |
AR065802A1 (es) | 2007-03-22 | 2009-07-01 | Schering Corp | Formulaciones de comprimidos que contienen sales de 8- [( 1- ( 3,5- bis- (trifluorometil) fenil) -etoxi ) - metil) -8- fenil -1, 7- diaza- spiro [ 4,5] decan -2- ona y comprimidos elaborados a partir de estas |
HUE026148T2 (en) | 2008-09-05 | 2016-05-30 | Opko Health Inc | 8 - ({1- [3,5-bis (trifluoromethyl) phenyl] ethoxy} methyl) -8-phenyl-1,7-diaza-spiro [4,5] decane-on-compounds intermediates |
ES2609640T3 (es) | 2009-08-14 | 2017-04-21 | Opko Health, Inc | Formulaciones intravenosas de rolapitant |
-
2008
- 2008-03-19 AR ARP080101154 patent/AR066191A1/es unknown
- 2008-03-20 MX MX2009010211A patent/MX2009010211A/es active IP Right Grant
- 2008-03-20 ES ES08742144.2T patent/ES2579771T3/es active Active
- 2008-03-20 WO PCT/US2008/003640 patent/WO2008118328A2/en active Application Filing
- 2008-03-20 SG SG2012046439A patent/SG182226A1/en unknown
- 2008-03-20 CN CN200880017063.0A patent/CN101679257B/zh not_active Expired - Fee Related
- 2008-03-20 US US12/531,859 patent/US8552191B2/en active Active
- 2008-03-20 JP JP2009554566A patent/JP5451404B2/ja not_active Expired - Fee Related
- 2008-03-20 EP EP08742144.2A patent/EP2137151B1/en active Active
- 2008-03-20 CN CN201410738810.7A patent/CN104447510B/zh not_active Expired - Fee Related
- 2008-03-20 CA CA2682221A patent/CA2682221C/en active Active
- 2008-03-20 EP EP16168286.9A patent/EP3138836A1/en not_active Withdrawn
-
2010
- 2010-04-15 HK HK10103699.6A patent/HK1136297A1/zh not_active IP Right Cessation
-
2013
- 2013-09-27 US US14/039,367 patent/US9260428B2/en active Active
- 2013-12-26 JP JP2013268922A patent/JP2014144951A/ja not_active Withdrawn
-
2016
- 2016-02-12 US US15/043,129 patent/US10000493B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
CN101679257B (zh) | 2015-01-07 |
AR066191A1 (es) | 2009-08-05 |
EP2137151B1 (en) | 2016-05-11 |
US8552191B2 (en) | 2013-10-08 |
WO2008118328A2 (en) | 2008-10-02 |
JP5451404B2 (ja) | 2014-03-26 |
US20170008893A1 (en) | 2017-01-12 |
CN104447510B (zh) | 2018-03-30 |
US10000493B2 (en) | 2018-06-19 |
WO2008118328A3 (en) | 2009-03-05 |
US9260428B2 (en) | 2016-02-16 |
CA2682221A1 (en) | 2008-10-02 |
EP2137151A2 (en) | 2009-12-30 |
HK1136297A1 (es) | 2010-06-25 |
CN101679257A (zh) | 2010-03-24 |
JP2014144951A (ja) | 2014-08-14 |
ES2579771T3 (es) | 2016-08-16 |
CN104447510A (zh) | 2015-03-25 |
SG182226A1 (en) | 2012-07-30 |
US20140024834A1 (en) | 2014-01-23 |
US20100087426A1 (en) | 2010-04-08 |
JP2010522171A (ja) | 2010-07-01 |
CA2682221C (en) | 2017-04-25 |
EP3138836A1 (en) | 2017-03-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2009010211A (es) | Proceso de intermediarios para la sintesis de compuestos 8-[{1-(3,5-bis-(trifluorometil)fenil)-etoxi}-metil]-8-fenil-1,7-d iaza-espiro[4.5]decan-2-ona. | |
MX2014001671A (es) | Compuestos fungicidas de 1-{2-[2-halo-4-(4-halogen-fenoxi)-fenil]- 2-aluiniloxi-etil}-1h[1,2,4]triazol sustituidos. | |
EP3981761A3 (en) | Intermediates for prodrugs | |
NZ601786A (en) | Novel compounds and compositions and methods of use | |
MX2010002244A (es) | Nuevos fungicidas. | |
MX341524B (es) | Pirrolobenzodiazepinas como compuestos pbd dimericos asimetricos para inclusion en conjugados dirigidos. | |
MX2010002243A (es) | Derivados fungicidas de 2-alquiltio-2-quinoliniloxi-acetamida. | |
MY172034A (en) | Intermediate for producing bicyclic ?-amino acid derivative | |
TW200800961A (en) | IAP bir domain binding compounds | |
JO2893B1 (en) | Chemical method | |
MX2009003698A (es) | Preparacion de azoxistrobina. | |
WO2007109810A3 (en) | Methods for the preparation of imidazole-containing compounds | |
NZ595591A (en) | Processes for the preparation of morphinane and morphinone compounds | |
HK1158623A1 (en) | Intermediates for the synthesis of 8-[1-(3,5-bis-(trifluoromethyl)phenyl)- ethoxy-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one compounds 8-[1-(35--())--]-8--17-- [45]-2- | |
EP3388426A3 (en) | Compounds for protection of cells | |
SG170838A1 (en) | Hydrochloride salts of 8-[{1-(3,5-bis-(trifluoromethyl) phenyl) -ethoxy}- methyl] -8-phenyl-1,7-diaza-spiro[4.5] decan-2-one and preparation process therefor | |
NZ593172A (en) | 4-azetidinyl-1-heteroaryl-cyclohexanol antagonists of ccr2 | |
MX347564B (es) | Proceso para la preparacion de n-metoxi-[1-metil-2-feniletil]amida s del acido 3-difluorometil-1-metil-1h-pirazol-4-carboxilico sustituidas con fenilo. | |
EP2865678A3 (en) | Crystalline hemi-tartrate form of a benzoimidazol-2-yl pyrimidine derivative | |
NZ600017A (en) | 5-hydroxypyrimidine-4-carboxamide derivative | |
MX2010001229A (es) | Procedimiento para la resolucion de zopiclona y compuestos intermedios. | |
WO2008033891A3 (en) | Azonafide derived tumor and cancer targeting compounds | |
EP2578617A4 (en) | NYLON CONNECTION | |
TN2011000474A1 (en) | Pyrazole compound | |
MX2013004193A (es) | Procedimiento para la preparacion de derivados de acido 3-(6-amino-piridin-3-il)-2-acrilico. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
HH | Correction or change in general | ||
GB | Transfer or assignment |
Owner name: OPKO HEALTH, INC. |
|
FG | Grant or registration |